RASolve 301: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Study-ID: NCT06881784

DZL Disease Area: LC

Study Type: Interventional

DZL Role: DZL recruiting center

Funding: Externally - industry

DZL Participating Sites: TLRC

Start Date: 06.05.2025

Completion Date: 01.12.2030

Status: Recruiting

DZL recruiting center

Disease: NSCLC

NCT Number: NCT06881784